Navigation Links
Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
Date:1/4/2012

BETHLEHEM, Pa., Jan. 4, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Edward L. Erickson, president and CEO of Saladax, will be presenting at the Biotech Showcase™ 2012 Conference being held in San Francisco, CA.  The presentation will be given on Wednesday, January 11, 2012 at 3:45 p.m. PST on the fourth floor of the Parc 55 Wyndham San Francisco Union Square hotel.  Mr. Erickson will provide an overview of the company's business, including its products, sales and marketing activities, strategic alliances and finances.

About My5-FU™

Saladax's first commercially available test for innovative dose management, My5-FU, measures levels of 5-flourouracil (5-FU), a widely prescribed chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and other side effects.

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems.  In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology. In addition the company is finalizing development of its next two oncology drug assays, for paclitaxel and docetaxel. Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.  For more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.

Saladax Biomedical, Inc.
Edward L. Erickson
President and Chief Executive Officer
eerickson@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Jason Rando
jrando@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Saladax Biomedical, Inc. Appoints Li Zhang, M.D., to Scientific Advisory Board
2. Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City
3. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
4. Saladax Biomedical, Inc. Announces European Commercialization Team
5. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
6. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
7. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
8. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
9. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
10. Cardium to Present at Upcoming Investor Conferences
11. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2019)... PINE BROOK, N.J. (PRWEB) , ... May 03, ... ... visual electrophysiology, announces the release of the Diopsys® ffERG/Photopic Negative Response ... signs of glaucoma. , By 2050, it is estimated that 6.3 million Americans ...
(Date:5/2/2019)... ... April 30, 2019 , ... The centuries old practice ... macro breweries to local craft breweries, and even home brewing clubs scattered across the ... and biological processes, that when mastered can produce a superb product. Students at ...
(Date:5/2/2019)... ... May 02, 2019 , ... ... will present results documenting discrepancies between U.S. insurer policies for genetic testing and ... risk for hereditary breast and ovarian cancer (HBOC). , Jill S. ...
(Date:4/25/2019)... ... April 23, 2019 , ... Frank is an albino, deaf Great Dane. His owners ... him due to his health issues. Despite his hearing impairment, he was always an active ... two would play all day, every day. As the two grew, playtime became rougher and ...
Breaking Biology Technology:
(Date:6/4/2019)... ... June 04, 2019 , ... Most preclinical EEG visualization ... risk signals, usually based on variations of amplitude, frequency or spike train detection. ... methodology due to the complexity and variability of the signal, and automation tools ...
(Date:5/31/2019)... ... May 30, 2019 , ... Researchers ... Mayo Clinic, have documented significant differences in the prevalence of hereditary genetic mutations, ... compared to non-Hispanic White women. Results will be presented at the 2019 American ...
(Date:5/24/2019)... ... 24, 2019 , ... The newest edition of Crystallography Times from ... global website. , Crystallography Times is a monthly electronic newsletter published by Rigaku Oxford ... analysis community by presenting the latest news and crystallographic research. , “Crystallography in ...
Breaking Biology News(10 mins):